Linezolid is one of the most used antibacterials to treat resistant gram-positive infections, though its use may result in a number of toxic effects, especially in the older adults. There is lack of data derived from the real-world studies regarding safety of linezolid in the elderly.
The aim
To disclose the structure of adverse drug reactions (ADRs) associated with linezolid in patients ≥60 years.
Materials and methods
Retrospective analysis of spontaneous reports (SRs) from the Russian Pharmacovigilance database (April 2019–December 2024).
Results
SRs of patients ≥60 years accounted up to 19.9% in the total structure of SRs. Top-5 system-organ classes (SOCs) were blood and lymphatic system disorders (24.4%, n = 68), gastrointestinal disorders (17.6%, n = 49), investigations (11.1%, n = 31), skin and subcutaneous tissue disorders (9.7%, n = 27), and general disorders and administration site conditions (6.1%, n = 17). Top-5 preferred terms (PTs) were thrombocytopenia (7.9%, n = 22), anemia (7.2%, n = 20), nausea 4.3% (n = 12), diarrhea (3.6%, n = 10), vomiting (3.6%, n = 10), and leukopenia (3.6%, n = 10).
Conclusions
Linezolid-induced myelosuppression was identified as the most significant safety concern in patients ≥60 years, underscoring the necessity for careful laboratory and clinical monitoring in this population.
HäderAKöse-VogelNSchulzL, et al.Respiratory infections in the aging lung: implications for diagnosis, therapy, and prevention. Aging Dis2023; 14(4): 1091–1104.
2.
UrbanBCGonçalvesANALoukovD, et al.Inflammation of the nasal mucosa is associated with susceptibility to experimental pneumococcal challenge in older adults. Mucosal Immunol2024; 17(5): 973–989.
3.
IbarzMHaasLEMCeccatoA, et al.The critically ill older patient with sepsis: a narrative review. Ann Intensive Care2024; 14(1): 6.
4.
ObianyoCMMuoghaluNAdjeiEM, et al.Trends and disparities in pneumonia-related mortality in the U.S. population: a nationwide analysis using the CDC WONDER data. Cureus2025; 17(5): e83371.
5.
CobertJJeonSYBoscardinJ, et al.Trends in geriatric conditions among older adults admitted to US ICUs between 1998 and 2015. Chest2022; 161(6): 1555–1565.
6.
Karakoç-ParlayanHNBulutDHaykır-SolayA, et al.An analysis of bacterial infection distribution in the elderly, and their clinical and laboratory profiles: aging and bacterial infection. Infect Dis Clin Microbiol2025; 7(1): 47–57.
7.
FalconeMTiseoG. Skin and soft tissue infections in the elderly. Curr Opin Infect Dis2023; 36(2): 102–108.
8.
HashemianSMRFarhadiTGanjparvarM. Linezolid: a review of its properties, function, and use in critical care. Drug Des Dev Ther2018; 12: 1759–1767.
9.
BiLQZhouJHuangM, et al.Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia. Pakistan J Med Sci2013; 29(3): 837–842.
10.
QinYChenZGaoS, et al.Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients. Eur J Hosp Pharm2024; 31(2): 94–100.
11.
ThirotHBriquetCFrippiatF, et al.Clinical use and adverse drug reactions of linezolid: a retrospective study in four Belgian hospital centers. Antibiotics (Basel)2021; 10(5): 530.
12.
ThirotHFageDLeonhardtA, et al.Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers. Front Pharmacol2024; 15: 1310309.
13.
ZouFCuiZLouS, et al.Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol2024; 15: 1338902.
14.
EimerJFréchet-JachymMLeDD, et al.Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment. Clin Infect Dis2023; 76(3): e947–e956.
15.
KeutzerLMockeliunasLSturkenboomMGG, et al.Derivation and clinical utility of safety targets for linezolid-related adverse events in drug-resistant tuberculosis treatment. Pharmaceuticals2023; 16(11): 1575.
16.
ButranovaOIUshkalovaEAZyryanovSK, et al.Pharmacokinetics of antibacterial agents in the elderly: the body of evidence. Biomedicines2023; 11(6): 1633.
17.
LiuTYuanYWangC, et al.Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study. J Antimicrob Chemother2024; 79(8): 1938–1950.
18.
BaiADMcKennaSWiseH, et al.Safety profile of linezolid in older adults with renal impairment: a population-based retrospective cohort study. Open Forum Infect Dis2022; 9(12): ofac669.
19.
LiuJPangYLiW, et al.Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion. Antimicrob Agents Chemother2025; 69: e01892–e01924.
ZhangDXuYWangX, et al.Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Eur J Clin Pharmacol2023; 79(10): 1303–1314.
24.
ZhangLYanYLiaoR, et al.Effect of platelet parameters on linezolid-related thrombocytopenia in hospitalized patients. Infect Drug Resist2023; 16: 6145–6154.
25.
Giunio-ZorkinNBrownG. Real-life frequency of new-onset thrombocytopenia during linezolid treatment. Can J Hosp Pharm2019; 72(2): 133–138, Epub 2018 Apr 30.
26.
ZhaoXXPengQHuD, et al.Prediction of risk factors for linezolid-induced thrombocytopenia based on neural network model. Front Pharmacol2024; 15: 1292828.
27.
WangYYeXLanQ, et al.UPLC-MS/MS determination of linezolid and heme in plasma of infected patients and correlation analysis. BioMed Res Int2021; 2021: 6679076.
28.
MaHGongZWuR, et al.Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study. Ther Adv Drug Saf2024; 15: 20420986241279128.
29.
QinYLiuYChenZ, et al.A risk factor-based predictive model for linezolid-induced anaemia: a 7-year retrospective study. J Clin Pharm Therapeut2021; 46(6): 1591–1599.
30.
DaiYJiangSChenX, et al.Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients. J Clin Pharm Therapeut2021; 46(3): 807–813.
31.
CattaneoDMarriottDJGervasoniC. Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations. Expet Rev Clin Pharmacol2023; 16(3): 219–230.
32.
PratamaNYIZulkarnainBSSoedarsonoFU, et al.Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. J Basic Clin Physiol Pharmacol2021; 32(4): 777–781.
33.
VeermanKGoosenJSpijkersK, et al.Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects. J Antimicrob Chemother2023; 78(11): 2660–2666.
34.
LeachKLSwaneySMColcaJR, et al.The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell2007; 26(3): 393–402.
35.
SharmaSSyalAGuptaM, et al.Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant Staphylococcus aureus. Cureus2020; 12(10): e10890.
36.
AbouHOKKarnibMEl-KhouryR, et al.Linezolid toxicity and mitochondrial susceptibility: a novel neurological complication in a Lebanese patient. Front Pharmacol2016; 7: 325.
37.
MilosevicTVPayenVLSonveauxP, et al.Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes. Antimicrob Agents Chemother2018; 62(3): e01599–e01617.
38.
MilosevicTVVertenoeilGVainchenkerW, et al.Oxazolidinone antibiotics impair ex vivo megakaryocyte differentiation from hematopoietic progenitor cells and their maturation into platelets. Antimicrob Agents Chemother2024; 68(10): e0053324.
39.
LiuXAokiMOsaS, et al.Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis. BMC Pharmacol Toxicol2022; 23(1): 89.
40.
ZhaoHTangLZhuangZ, et al.A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment. Sci Rep2024; 14(1): 26064. Published 2024 Oct 30.
41.
LinBHuYXuP, et al.Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health2022; 10: 967311.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
